Nutex Health Appoints New Chief Medical Officer

TL;DR

Nutex Health names Dr. John H. Wilson as new CMO, effective Sept 2.

AI Summary

Nutex Health, Inc. announced on September 4, 2025, that its Board of Directors appointed Dr. John H. Wilson as Chief Medical Officer, effective September 2, 2025. Dr. Wilson will also serve as a member of the company's executive management team. This appointment is part of the company's ongoing efforts to strengthen its leadership in the healthcare sector.

Why It Matters

The appointment of a new Chief Medical Officer can signal a strategic shift or renewed focus on clinical operations and patient care, potentially impacting the company's future growth and market position.

Risk Assessment

Risk Level: low — This filing reports a routine executive appointment, which typically carries low inherent risk.

Key Players & Entities

• Nutex Health, Inc. (company) — Registrant
• Dr. John H. Wilson (person) — Appointed Chief Medical Officer
• September 4, 2025 (date) — Date of Report
• September 2, 2025 (date) — Effective date of appointment
• Delaware (jurisdiction) — State of Incorporation
• Houston, Texas (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value NUTX NASDAQ Capital Market

Filing Documents

• nutx-20250904.htm (8-K) — 22KB
• 0001479681-25-000072.txt ( ) — 138KB
• nutx-20250904.xsd (EX-101.SCH) — 2KB
• nutx-20250904_lab.xml (EX-101.LAB) — 22KB
• nutx-20250904_pre.xml (EX-101.PRE) — 13KB
• nutx-20250904_htm.xml (XML) — 3KB

From the Filing

nutx-20250904 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): September 4, 2025 (September 2, 2025) NUTEX HEALTH INC. (Exact name of registrant as specified in its charter) Delaware 001-41346 11-3363609 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification Number) 6030 S. Rice Ave , Suite C , Houston , Texas 77081 (Address of principal executive offices) (zip code) ( 713 ) 660-0557 (Registrant's telephone number, including area code) N/A (Former name or former address, if changed since last report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Precommencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Precommencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbols(s) Name of each exchange on which registered Common Stock, $0.001 par value NUTX NASDAQ Capital Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 2, 2025, the Board of Directors (the "Board") of Nutex Health, Inc. (the "Company") appointed Michael L. Reed, as the Lead Independent Director of the Board, effective immediately. Mr. Reed will serve in this role until his successor is duly elected and qualifies, unless he sooner dies, retires or resigns. Mr. Reed has served as a member of the Company's Board since April 2022 and is currently a member of the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. In his role as Lead Independent Director, Mr. Reed will undertake responsibilities consistent with the Company's corporate governance guidelines and Nasdaq Listing Rule 5605, including presiding over executive sessions of the independent directors, facilitating communication between the independent directors and the Chairman of the Board and Chief Executive Officer, and serving as a liaison between the Board and the Company's management. This appointment reinforces the Company's commitment to robust corporate governance practices and compliance with Nasdaq's requirements for independent board leadership. There are no arrangements or understandings between Mr. Reed and any other persons pursuant to which he was selected as Lead Independent Director. There are no family relationships between Mr. Reed and any director or executive officer of the Company, and there are no transactions involving Mr. Reed that would require disclosure under Item 404(a) of Regulation S-K. Mr. Reed will receive additional compensation for his role as Lead Independent Director, consistent with the Company's director compensation program as disclosed in its most recent proxy statement filed with the Securities and Exchange Commission on June 2, 2025. The compensation includes an annual retainer, payable in cash and/or equity awards, as determined by the Board's Compensation Committee. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. Date: September 4, 2025 Nutex Health Inc. By: /s/ Jon C. Bates Jon C. Bates Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR